BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

Stock Information for BioVaxys Technology Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioVaxys Technology Corp.

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
BioVaxys Announces Application for Management Cease Trade Order
BioVaxys 1Q2026 R&D and Collaborative Activity
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
2025 Corporate Review
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.